GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cleveland BioLabs Inc (NAS:CBLI) » Definitions » YoY EPS Growth

Cleveland BioLabs (Cleveland BioLabs) YoY EPS Growth : 20.00% (As of Mar. 2021)


View and export this data going back to 2006. Start your Free Trial

What is Cleveland BioLabs YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cleveland BioLabs's YoY EPS Growth for the quarter that ended in Mar. 2021 was 20.00%.

Cleveland BioLabs's Earnings per Share (Diluted) for the three months ended in Mar. 2021 was $-0.04.


Cleveland BioLabs YoY EPS Growth Historical Data

The historical data trend for Cleveland BioLabs's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleveland BioLabs YoY EPS Growth Chart

Cleveland BioLabs Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.59 -262.50 63.22 28.13 17.39

Cleveland BioLabs Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.50 40.00 -50.00 16.67 20.00

Cleveland BioLabs YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cleveland BioLabs's YoY EPS Growth for the fiscal year that ended in Dec. 2020 is calculated as:

YoY EPS Growth (A: Dec. 2020 )
=(Earnings per Share (Diluted) (A: Dec. 2020 )-Earnings per Share (Diluted) (A: Dec. 2019 ))/ | Earnings per Share (Diluted) (A: Dec. 2019 ) |
=(-0.19--0.23)/ | -0.23 |
=17.39 %

Cleveland BioLabs's YoY EPS Growth for the quarter that ended in Mar. 2021 is calculated as:

YoY EPS Growth (Q: Mar. 2021 )
=(Earnings per Share (Diluted) (Q: Mar. 2021 )-Earnings per Share (Diluted) (Q: Mar. 2020 )) / | Earnings per Share (Diluted) (Q: Mar. 2020 )) |
=(-0.04--0.05)/ | -0.05 |
=20.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleveland BioLabs YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Cleveland BioLabs's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleveland BioLabs (Cleveland BioLabs) Business Description

Traded in Other Exchanges
N/A
Address
73 High Street, Buffalo, NY, USA, 14203
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Executives
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Randy S. Saluck director C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Tatiana Levina director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Ivan Persiyanov director 4 SADOVNICHESKAYA ST, MOSCOW 1Z 115035
Anna Evdokimova director 9-96 UNIVERSITETSKIY PROSPEKT, MOSCOW 1Z 119296
Yulia Lebedina director 5 MALYSHEVA STREET, FLAT 7, MOSCOW 1Z 109129
Konstantin Gorshkov director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Saraeva director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Khudyk director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031

Cleveland BioLabs (Cleveland BioLabs) Headlines